The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.

This Project is designed to identify biologically-based and clinically-useful biomarkers of tissue at risk for neoplastic progression as well as of response to ablation therapy. These results will result in improved risk stratification in BE and better targeting of resources for patients who are candidates for ablative therapy, while simultaneously providing key information regarding the origins of Barrett's esophagus.

Inclusion Criteria:

• Barrett's esophagus with high grade dysplasia or intramucosal (early) adenocarcinoma.
• BE length ≥ 2 cm and ≤ 8 cm.
• Able to return every 3 months for one year after ablation

Exclusion Criteria:

• Patients who are unable to be compliant with follow-up endoscopies
• patients who cannot tolerate Proton Pump inhibitors
• pre-existing esophageal strictures
• pregnant or nursing women

Participants must have biopsy proven Barret's esophgus with evidence of specialized intestinal epithelium with high grade dysplasia or early intramucosal carcinoma (mEAC) on histology (confirmed by two pathologists). Patients must have a BE length ≥ 2 cm and ≤ 8 cm.